222 related articles for article (PubMed ID: 36348350)
1. Elevation of spermine remodels immunosuppressive microenvironment through driving the modification of PD-L1 in hepatocellular carcinoma.
Shi HX; Liang C; Yao CY; Gao ZX; Qin J; Cao JL; Zhang MZ; Li YY; Wang MQ; Sun H; Xie SQ; Fang D
Cell Commun Signal; 2022 Nov; 20(1):175. PubMed ID: 36348350
[TBL] [Abstract][Full Text] [Related]
2. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
[TBL] [Abstract][Full Text] [Related]
3. LAIR1-mediated resistance of hepatocellular carcinoma cells to T cells through a GSK-3β/β-catenin/MYC/PD-L1 pathway.
Pan B; Ke X; Qiu J; Ye D; Zhang Z; Zhang X; Luo Y; Yao Y; Wu X; Wang X; Tang N
Cell Signal; 2024 Mar; 115():111039. PubMed ID: 38199599
[TBL] [Abstract][Full Text] [Related]
4. Dickkopf-1 drives tumor immune evasion by inducing PD-L1 expression in hepatocellular carcinoma.
Yang RH; Qin J; Cao JL; Zhang MZ; Li YY; Wang MQ; Fang D; Xie SQ
Biochem Pharmacol; 2023 Feb; 208():115378. PubMed ID: 36513141
[TBL] [Abstract][Full Text] [Related]
5. SYVN1 ubiquitinates FoxO1 to induce β-catenin nuclear translocation, PD-L1-mediated metastasis, and immune evasion of hepatocellular carcinoma.
Xie W; Shi L; Quan H; Xiao H; Chen J; Liu J; de Dieu Habimana J; Huang R; Luo J; Chen P; Li Z
Cell Oncol (Dordr); 2023 Oct; 46(5):1285-1299. PubMed ID: 37099251
[TBL] [Abstract][Full Text] [Related]
6. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
[TBL] [Abstract][Full Text] [Related]
7. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
8. PA-MSHA Regulates PD-L1 Expression in Hepatoma Cells.
Wei H; Mao Y; Zhang H; Wu F; Zhang Y
Immunol Invest; 2023 Apr; 52(3):343-363. PubMed ID: 36762677
[TBL] [Abstract][Full Text] [Related]
9. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression.
Peng L; Pan B; Zhang X; Wang Z; Qiu J; Wang X; Tang N
Cell Biol Toxicol; 2022 Dec; 38(6):1159-1173. PubMed ID: 35438468
[TBL] [Abstract][Full Text] [Related]
10. FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer.
Wang D; Wu S; He J; Sun L; Zhu H; Zhang Y; Liu S; Duan X; Wang Y; Xu T
J Exp Clin Cancer Res; 2023 Sep; 42(1):222. PubMed ID: 37658376
[TBL] [Abstract][Full Text] [Related]
11. Programmed death ligand 1 regulates epithelial-mesenchymal transition and cancer stem cell phenotypes in hepatocellular carcinoma through the serum and glucocorticoid kinase 2/β-catenin signaling pathway.
Kong X; Peng H; Liu P; Fu X; Wang N; Zhang D
Cancer Sci; 2023 Jun; 114(6):2265-2276. PubMed ID: 36751987
[TBL] [Abstract][Full Text] [Related]
12. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
[TBL] [Abstract][Full Text] [Related]
13. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
14. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma.
Yu J; Ling S; Hong J; Zhang L; Zhou W; Yin L; Xu S; Que Q; Wu Y; Zhan Q; Bao J; Xu N; Liu Y; Chen K; Wei X; Liu Z; Feng T; Zhou L; Xie H; Wang S; Liu J; Zheng S; Xu X
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030304
[TBL] [Abstract][Full Text] [Related]
15. Spermidine/spermine N1-acetyltransferase regulates cell growth and metastasis via AKT/β-catenin signaling pathways in hepatocellular and colorectal carcinoma cells.
Wang C; Ruan P; Zhao Y; Li X; Wang J; Wu X; Liu T; Wang S; Hou J; Li W; Li Q; Li J; Dai F; Fang D; Wang C; Xie S
Oncotarget; 2017 Jan; 8(1):1092-1109. PubMed ID: 27901475
[TBL] [Abstract][Full Text] [Related]
16. MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapy.
Wan JL; Wang B; Wu ML; Li J; Gong RM; Song LN; Zhang HS; Zhu GQ; Chen SP; Cai JL; Xing XX; Wang YD; Yang Y; Cai CZ; Huang R; Liu H; Dai Z
Cancer Lett; 2022 Aug; 541():215750. PubMed ID: 35609735
[TBL] [Abstract][Full Text] [Related]
17. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
18. Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment.
Li H; You J; Wei Y; Zheng L; Yang J; Xu J; Li Y; Li Z; Yang X; Yi C
Phytomedicine; 2024 Jan; 123():155189. PubMed ID: 37984124
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells.
Tanaka T; Koga H; Suzuki H; Iwamoto H; Sakaue T; Masuda A; Nakamura T; Akiba J; Yano H; Torimura T; Kawaguchi T
Hepatol Int; 2024 Jun; 18(3):984-997. PubMed ID: 37553470
[TBL] [Abstract][Full Text] [Related]
20. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo.
Xu H; Chen Y; Li Z; Zhang H; Liu J; Han J
Eur J Pharmacol; 2022 Sep; 930():175154. PubMed ID: 35868447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
